NUVB - BTIG assumes coverage of Immuno-oncology companies; OncoSec gains on Buy rating

BTIG analyst Kaveri Pohlman assumed coverage of Replimune Group (NASDAQ:REPL) with a Buy rating and $60 price target (PT), implying a premium of ~93% from last close. The analyst assumed coverage of 10 more Immuno-oncology companies, and believes "much of the most promising work" involves broader immune involvement in the anti-tumor battle either involving or in combination with less-systemically toxic therapeutic cytokines. Pohlman assumed coverage of Seagen (NASDAQ:SGEN) with a Neutral rating and no price target. OncoSec Medical (NASDAQ:ONCS), up 4.3% premarket was assumed with a Buy rating and $10 PT, which is more than 5-fold higher than last closing price. Nuvation Bio (NYSE:NUVB) was assumed with a Buy rating and $16 PT, an increase of 69% from yesterday's close. Mersana Therapeutics (NASDAQ:MRSN) assumed with a Buy rating and $32 PT, which implies a premium of ~278% from last close. MacroGenics (NASDAQ:MGNX) assumed with a Buy rating and $50 PT, representing a

For further details see:

BTIG assumes coverage of Immuno-oncology companies; OncoSec gains on Buy rating